Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07562217

Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis (LIAISE Study)

The LIAISE study is a prospective observational study comparing the performance of load-incorporating echocardiographic parameters and conventional parameters in predicting adverse events among adult patients presenting to the ICU with sepsis. It will be conducted in hospitals in Australia, Hong Kong, South Africa, and Canada, with 199 patients recruited over 2 years. All included patients will receive an regular echocardiographic assessment and their haemodynamic parameters will be simultaneously recorded. Participants will be followed for up to 1 year after enrolment. Load incorporating parameters will be derived from regularly obtained echocardiography and haemodynamic data during offline analysis. The predictive value of cardiac parameters will be evaluated based on their statistical association with clinical outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Prince Charles Hospital

Chermside, Queensland, 4032, Australia

Location contact

Hideaki Nonaka, Dr

CONTACT

[email protected]

+61 449967910

Nonaka

CONTACT

About this study

Background Sepsis is a global killer, whereby an infection spreads throughout the body via the bloodstream. It often leads to lethal heart damage, "septic cardiomyopathy", with mortality rates for those affected soaring above 40%. To facilitate early and appropriate intervention for damaged hearts and improve their outcomes, accurate assessment of heart function, and proper prediction of their adverse events are crucial. However, conventional cardiac assessments cannot capture heart dysfunction accurately since they have a significant limitation called "load-dependency", which means these parameters' values are affected by loading conditions on the heart, such as blood pressure and circulating blood volume. In sepsis, as these loads on the heart dramatically change minute by minute, the values of cardiac assessment also fluctuate and frequently underestimates heart damage, failing to properly predict their adverse events. To address this, novel load-incorporating echocardiographic parameters can capture heart function more accurately regardless of these hemodynamic conditions, and previous data has demonstrated its better predictive value in cardiogenic shock cases where loading conditions similarly fluctuate. As a next step, this study seeks to elucidate their utility in patients with sepsis.

Aims

  • To investigate if novel load-incorporating echocardiography can predict adverse events more accurately than conventional parameters in adult patients with sepsis presenting to intensive care units (ICUs).
  • To identify the most sensitive cardiac parameter to predict adverse events in sepsis, from comprehensively collected cardiac parameters along with novel-incorporating echocardiography.

Hypothesis Load-incorporating echocardiographic parameters will be more accurate in predicting the incidence of adverse events within 30 days after ICU admission than conventional echocardiographic parameters.

Outcomes Primary outcome The incidence of all-cause death for 30 days after ICU admission

Secondary outcomes

  • Incidence of and time to all-cause death or cardiovascular readmission for 1 year after ICU admission
  • Incidence and duration of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission.
  • Reversibility of cardiac function (LVEF increases ≥ 5% in echo 3-5 days after ICU admission)
  • Sequential Organ Failure Assessment (SOFA) score at 3 days after ICU admission

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥ 18 years old.
  • Clinically suspected of defined sepsis
  • Sepsis-induced hypotension or hypoperfusion (arterial or venous blood lactate ≥2.0 mmol/L OR mean artery pressure ≤65 mmHg over 30 mins OR at least one vasoactive or inotropic agent administered).
  • At least one dose of an IV antimicrobial has been commenced.

Exclusion criteria

  • Suspected or confirmed pregnancy.
  • Any severe concomitant diseases with limited life expectancy <30 days.

Treatment and study plan

Primary outcomes

  1. All cause death

    Time frame: Day 30 after ICU admission

Secondary outcomes

  1. All cause death and adverse cardiac event readmission

    Time frame: 1 year after ICU admission

    Incidence of and time to all-cause death or adverse cardiac event readmissions for 1 year after ICU admission

  2. Mechanical circulartory suport, mechanical ventilation, renal replacement therapy, and vasoactive/inotropic agent therapy

    Time frame: during the initial index admission, between Day 0 and Day 30

    Incidence and duration (days) of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission

  3. Reversibility of cardiac function

    Time frame: Day 3 to Day 5

    Left ventricular ejection fraction increases ≥ 5% in echo from 3-5 days after ICU admission

  4. Sequential Organ Failure Assessment score at 3 days after ICU admission

    Time frame: at Day 3 of ICU admission

    Sequential Organ Failure Assessment score at Day 3 of index ICU admission will be assessed on a scale from 0 to 24, with higher scores indicating more severe organ failure.

Other outcomes

  1. lengh of hosiptal or ICU stay

    Time frame: during the initial index admission, between Day 0 and Day 30

  2. In-hospital mortariy

    Time frame: during the initial index admission, between Day 0 and Day 30

  3. Vasoactive-inotropic score at 24, and 48 hours

    Time frame: at 24 hour and 48 hour of index ICU admission

  4. Amount of fluid administered for the first 24 hours in ICU admission

    Time frame: Day 1 of index ICU admission

    CSL

Study contacts

Contact information is provided by the study sponsor or research team.

Hideaki Nonaka, Dr

CONTACT

[email protected]

+61 449967910

Nonaka

CONTACT

Sponsors and collaborators

Lead sponsor

The University of Queensland

Other

Collaborators

  • Queen Mary Hospital, Hong Kong

Registry information

Official study title

Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis: a Prospective Observational Study (LIAISE Study)

Acronym: LIAISE

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 1, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.